Patent Pending · Working Prototype

The vital sign
the world is missing.

A universal immune activation monitor, real-time,
~$1 per test, no lab required. Starting with neonatal sepsis the most urgent and underserved diagnostic need in medicine.

Request a Meeting ↗ See the Science
Working Prototype — NeutroScope Monitor
NeutroScope Labs device and companion app Device.png not found
~$1
Per test (consumable cost)
<5 min
Time to result
$15-47B
POC market
The Problem

Current tests fail where it matters most.

Neonatal sepsis kills millions. Yet the diagnostic tools clinicians rely on are slow, expensive, infrastructure-heavy and often inaccurate  costing precious hours when every minute counts.

⏱️

24–48 Hour Turnaround

Standard CRP and complete blood count tests require lab infrastructure and take far too long in sepsis emergencies where time equals survival.

💸

$120–$200 Per Test

Newer specialized sepsis tests cost $120–$200 per test, prohibitive for global health applications.

🏥

Requires Lab Infrastructure

Existing tests need trained personnel and specialized equipment unavailable in most NICUs in low and middle-income countries.

🎯

Inaccurate Readout

CRP and CBC provide indirect inflammation markers, missing the earliest and most specific signal: neutrophil activation state.

Our Solution

Measure immune activation
directly, in minutes.

NeutroScope measures neutrophil activation in whole blood using ultra-sensitive photonics the earliest measurable signal across virtually every major disease category.

🔬

Ultra-Sensitive Optical Detection

Proprietary photon emission measurement captures neutrophil activation state directly in whole blood with no sample preparation.

Patent Pending
⚡

Real-Time Results

Results in under 5 minutes. Validated in both murine and human blood with clear separation between activated and control states.

<5 min
🧑‍⚕️

No Training Required

Stick blood test, very small sample volume. Any clinical staff member can operate the device, no specialist technician needed.

Point-of-Care
💡

Disruptive Cost Structure

~$1 per test. Razor & blades model maximizes recurring revenue.

~$1 / test
Why Now

The technology was not possible five years ago.

Three converging shifts made real-time immune activation monitoring viable for the first time and NeutroScope is the first to capture them in a single device.

1

Cheaper Photonic Sensors

Photonic sensor cost has fallen sharply over the past decade, enabling ultra-sensitive detection at consumer-grade price points.

2

Neutrophils as Diagnostic Markers

Landmark research (Fridlender & Granot, Nature Cell Mol Immunol 2024) demonstrated neutrophil activation as the earliest measurable signal across infection, inflammation, autoimmunity, and cancer.

3

Microfluidics at Scale

Single-use microfluidic manufacturing costs have dropped dramatically as the technology matured, making disposable cartridges economically viable.

Validated Data

Proof of Concept 

Working prototype validated with imurine and human blood. Clear photon emission signal distinguishes healthy from inflamed states and tracks treatment response in real time.

Murine Blood · Detection

Immune Activation Signal

Cont.
Inflam.

3× photon emission increase in inflamed vs. control murine blood. Statistically significant separation confirmed.

Murine Blood · Treatment

Treatment Efficacy Tracking

Cont.
Treated

Real-time evaluation of treatment efficacy, signal drops to near-baseline 3 hours post-treatment.

Human Blood · Kinetics

Photon Emission Kinetics

Cont.
+PMA

PMA-activated human blood shows 4–6× photon emission vs. control over 8 minutes - clear, reproducible signal.

Pipeline & Vision

A universal immune activation monitor.

1 platform. 4 massive markets. Starting where the need is most acute.

Platform TAM - the optionality investors are buying, not a single diagnostic.

Entry Point
Neonatal Sepsis
~$65M initial market
→
Expansion
Adult ICU & Sepsis
~$4.5B
→
Growth
Autoimmune & IBD
$8B+ monitoring
→
Platform
Cancer Immunotherapy
$15B+ combined
Adult Sepsis & ICU

49M sepsis cases / 11M deaths per year. Real-time treatment guidance, not just diagnosis.

Autoimmune / IBD

Neutrophils flag IBD, RA, and lupus flares, disease activity measured at point of care.

Cancer Immunotherapy

Surrogate biomarker for checkpoint inhibitor response via the tumor microenvironment.

Infectious Disease Triage

Malaria, TB, COVID, first-line triage without a laboratory, anywhere in the world.

Market Opportunity

A $29.7B addressable market - starting at the sharpest pain point.

Entry through neonatal sepsis in high-incidence regions, expanding to developed-world hospital systems where the same device commands $10–100/test pricing.

$65M
Neonatal sepsis entry market (99M births, $1/test)
$29.7B
Next addressable: US + EU + Japan hospitals & clinics
$15-47B
Annual global Point-of-Care diagnostics market (2025)
99M
Annual births in neonatal sepsis target regions
Facility Type US+EU+Japan Annual Revenue
Hospitals 26,600 $8.8B (US)
Clinics 385,000 $14.5B (EU)
Independent Labs 25,000 $6.4B (Japan)
Total — $29.7B
Competitive Landscape

Real-time results.
100× cheaper.

Every competing product sacrifices either speed or cost. NeutroScope delivers both backed by a novel measurement modality no competitor uses.

Real-time results (<5 min) vs. 24–48 hrs for standard tests
~$1/test vs. $120–$200 for specialized competitors
No lab infrastructure or trained technician required
Measures neutrophil activation, not a downstream proxy
Razor & blades model: recurring high-margin consumable revenue
Product Time Cost/Test
CRP (standard) 24–48 hrs $9–79
Competitor 1 60 min ~$120
Competitor 2 5–7 min ~$200
Competitor 3 30 min ~$150
NeutroScope Labs <5 min ~$1
The Team

World-class science.
Deep MedTech execution.

The founding team combines 60+ years of combined IP, deep academic credibility in neutrophil biology, and serial MedTech operating experience.

Prof. Zvika Granot

Prof. Zvika Granot, PhD

Co-Founder · Chief Scientific Officer

Professor at Hebrew University of Jerusalem. World-renowned immunologist and expert in neutrophil biology, inflammatory diseases, and cancer immunology. Founded Immunyx Pharma (2020).

4 Patents · Hebrew University
Asaf Granot

Asaf Granot

Co-Founder · Chief Technology Officer

MSc Applied Optics · BSc Physics & Computer Science. 20+ years in semiconductor and MedTech industries across Boston Scientific (Lumenis), KLA, Sarine, and Tower Semiconductors.

13 Patents · Applied Optics
Eyal Sheetrit

Eyal Sheetrit

Co-Founder · Chief Executive Officer

MBA | MSc. 20+ years in Biotech & MedTech. Ex-Senior Management at Johnson & Johnson. Former Co-Founder & CEO of Eximore and FiberSpin. Deep investor network across the sector.

8 Patents · J&J · Eximore · MBA | MSc
Get In Touch

Ready to change how the world reads its immune system?

We're actively meeting with investors, strategic partners, and key opinion leaders. Reach out to schedule a deeper dive, request our full deck, or discuss collaboration opportunities.

Request Full Deck ↗ Talk to Eyal
Prof. Zvika Granot, PhD
Co-Founder · Science
+972-522-676-712 zvika@neutroscopelabs.com
Asaf Granot
Co-Founder · Technology
+972-504-434-243 asaf@neutroscopelabs.com
Eyal Sheetrit
Co-Founder · Business
+972-542-342-644 eyal@neutroscopelabs.com